Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological standardization of five grass pollen allergen extracts in sensitized patients
2014-001210-26Phase 2Completed
- Sponsor
- Probelte Pharma
- Start
- May 2015
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of dactylis glomerata allergen extract, Festuca pratensis pollen, lolium allergen extract, allergovac depot, poa pratensis allergen extract and 1 more in grass pollen allergy (5 cohorts), sponsored by Probelte Pharma. Primary endpoint: Biological standardization target. Started May 2015; status: completed.
02
Drugs
dactylis glomerata allergen extractFestuca pratensis pollenlolium allergen extractallergovac depotpoa pratensis allergen extract
03
Conditions
grass pollen allergy
Beyond the preview
Go deeper on 2014-001210-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001210-26.